TSC for hemorrhagic shock: effects on cytokines and blood pressure.
Previous studies have shown that administering trans-sodium crocetinate (TSC) as a treatment of hemorrhagic shock leads to increased whole-body oxygen consumption and survival as well as protection of the liver and kidney. It has been suggested that TSC increases oxygen delivery by increasing the diffusivity of oxygen through plasma. However, as with any novel mechanism of action, there are always questions about whether the results could also be ascribed to other, previously described mechanisms of action. This study was designed to look at some aspects of that by examining the effect of different TSC dosing regimens on the blood pressure and the production of cytokines after hemorrhage because both responses have been reported with compounds that act via other mechanisms. In a constant-pressure rat model of hemorrhagic shock, it was seen that a singe bolus injection of TSC results in an immediate but transient increase in the arterial blood pressure. This is similar to the effect reported previously for using 100% oxygen. It was also found that if the TSC injections were repeated periodically over an hour, a sustained increase in the blood pressure would occur. Because inflammatory cytokines have been implicated in mortality and tissue damage, it has been suggested that TSC may affect the production of cytokines. Thus, the effect of TSC on the production of TNF-alpha and IL-10 was also examined. The data show that treatment with TSC results in lower concentrations of TNF-alpha in the liver and spleen as well as lower concentrations of IL-10 in the spleen. Again, similar effects on other cytokines have been seen with 100% oxygen. These results support the hypothesis that the effects of TSC on hemorrhagic shock are mediated via an effect on oxygen.
Stennett
Amanda K
AK
Department of Chemical Engineering, University of Virginia, Charlottesville, Virginia 22904-4741, USA.
Gainer
John L
JL
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D002338:Carotenoids; D016207:Cytokines / Q000378:metabolism*; D006339:Heart Rate / Q000187:drug effects; D016753:Interleukin-10 / Q000378:metabolism; D008297:Male; D010100:Oxygen / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012771:Shock, Hemorrhagic / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014801:Vitamin A / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use*
D016207:Cytokines; D014409:Tumor Necrosis Factor-alpha; C487773:trans-sodium crocetinate; D014801:Vitamin A; D016753:Interleukin-10; D002338:Carotenoids; D010100:Oxygen